BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

curasan AG (DX:CUR) Receives Approval for Cerasorb(R) M ORTHO in Canada


11/18/2010 2:46:52 PM

Kleinostheim, Germany, 18th November 2010 – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada.

“This news has come as a pleasant surprise”, stated Hans Dieter Rössler, CEO. “Since the approval process for medical devices by the Canadian authorities is highly demanding, we were actually expecting the certification some time next year.”

Cerasorb® M ORTHO is now approved for sales in the whole of North America. Furthermore, curasan AG considers that the experience gained with the authorities in Canada will be useful and beneficial for other product approvals in this market. This is a significant development for potential sales partners since further new bio materials are expected to be available earlier for market launch.

Background information about curasan AG:

Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.

Press Contact:

curasan AG Andrea Weidner Tel. +49 (0)6027 40 900-51 Fax +49 (0)6027 40 900-39 andrea.weidner@curasan.de www.curasan.de

fr financial relations gmbh Jörn Gleisner Tel. +49 (0)69 95 90 83 20 Fax +49 (0)69 95 90 83 99 j.gleisner@finanical-relations.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES